Charles Schwab Investment Management Inc. Purchases New Shares in Inozyme Pharma, Inc. (NASDAQ:INZY)

Charles Schwab Investment Management Inc. purchased a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) during the 3rd quarter, Holdings Channel reports. The fund purchased 48,334 shares of the company’s stock, valued at approximately $1,271,000.

A number of other large investors have also bought and sold shares of INZY. NEA Management Company LLC bought a new stake in shares of Inozyme Pharma in the 3rd quarter valued at $64,263,000. Sofinnova Investments Inc. purchased a new stake in Inozyme Pharma during the third quarter valued at about $53,324,000. BlackRock Inc. purchased a new stake in shares of Inozyme Pharma in the third quarter worth about $13,169,000. Sphera Funds Management LTD. purchased a new stake in shares of Inozyme Pharma in the third quarter worth about $5,164,000. Finally, Yale University purchased a new stake in shares of Inozyme Pharma in the third quarter worth about $2,984,000. Institutional investors and hedge funds own 13.03% of the company’s stock.

Shares of NASDAQ INZY opened at $20.64 on Friday. The stock has a 50 day moving average price of $24.50. Inozyme Pharma, Inc. has a twelve month low of $16.10 and a twelve month high of $31.65.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($1.04). As a group, analysts anticipate that Inozyme Pharma, Inc. will post -4.87 earnings per share for the current year.

Separately, Zacks Investment Research downgraded Inozyme Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, November 17th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $36.00.

About Inozyme Pharma

Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis.

Further Reading: Basic Economics

Want to see what other hedge funds are holding INZY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inozyme Pharma, Inc. (NASDAQ:INZY).

Institutional Ownership by Quarter for Inozyme Pharma (NASDAQ:INZY)

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.